Group a streptococcal vaccine candidates: potential for the development of a human vaccine.
Curr Top Microbiol Immunol
; 368: 207-42, 2013.
Article
em En
| MEDLINE
| ID: mdl-23250780
ABSTRACT
Currently there is no commercial Group A Streptococcus (GAS; S. pyogenes) vaccine available. The development of safe GAS vaccines is challenging, researchers are confronted with obstacles such as the occurrence of many unique serotypes (there are greater than 150 M types), antigenic variation within the same serotype, large variations in the geographical distribution of serotypes, and the production of antibodies cross-reactive with human tissue which can lead to host auto-immune disease. Cell wall anchored, cell membrane associated, secreted and anchorless proteins have all been targeted as GAS vaccine candidates. As GAS is an exclusively human pathogen, the quest for an efficacious vaccine is further complicated by the lack of an animal model which mimics human disease and can be consistently and reproducibly colonized by multiple GAS strains.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Streptococcus pyogenes
/
Vacinas Estreptocócicas
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Top Microbiol Immunol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Austrália